“Ozempic Santa.” Musk elaborated in a follow-up post he is technically using the Eli Lilly weight-loss drug Mounjaro over Novo Nordisk’s Ozempic, “but that doesn’t have the same ring to it.

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Elon Musk shared a photo dressed as Santa Claus, engaging social media users. He compared this look with a childhood Santa photo, receiving praise and humorous comments. The posts, shared on X ...

The launch of Mounjaro always raised the risk that it would cannibalise sales of Lilly's own GLP-1 agonist Trulicity (dulaglutide), which is competing head-to-head with Ozempic in the market ...

which will help it meet what it anticipates will be rising demand for Mounjaro and other drugs in its incretin franchise, notably blockbuster GLP-1 agonist Trulicity (dulaglutide). "Expanding our ...

but Santa and Ozempic!,” before admitting in another post that it was “technically Mounjaro” that he was using. He added that it “doesn’t have the same ring to it.” This prompted ...

The clear laggard has been Trulicity, a diabetes/weight loss drug that has been cannibalized by the surge in sales for Mounjaro and Zepbound. In Q3, Trulicity sales tumbled by 22% to $1.30 bln. The ...

Roughly $15 billion of this total stems from just three drugs -- Mounjaro, Zepbound, and Trulicity. All of these are medications in Lilly's weight loss portfolio. However, another star performer ...